We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Intravitreal Bevacizumab for Inflammatory Neovascular Membranes

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00407121
First Posted: December 4, 2006
Last Update Posted: December 4, 2006
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Asociación para Evitar la Ceguera en México
  Purpose
Intravitreal injection of Bevacizumab in patients with Neovascular Membranes secondary to intraocular inflammation. We injected a single injection of Bevacizumab (2.5 mg/0.1 ml) and evaluate visual acuity , Fluorescein angiogram and retinal thickness by Optical Coherence Tomography (OCT) in 4 patients with Vogt Koyanagi Harada disease, 1 patient with Serpiginous Choroidopathy and 1 patient with Multifocal Choroiditis.

Condition Intervention Phase
Vogt Koyanagi Harada Disease Serpiginous Choroiditis Multifocal Choroiditis Drug: Bevacizumab Procedure: Intravitreal Injection of Bevacizumab Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Intravitreal Bevacizumab for the Treatment of Neovascular Membranes in Patients With Intraocular Inflammation

Resource links provided by NLM:


Further study details as provided by Asociación para Evitar la Ceguera en México:

Primary Outcome Measures:
  • Best corrected visual acuity
  • Retinal thickness by OCT
  • Leakage in Fluorescein angiogram

Study Start Date: August 2006
Estimated Study Completion Date: November 2006
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   25 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Clinical Diagnose
  • Patient Consent
  • Chronic stage of inflammation

Exclusion Criteria:

  • only eye
  • age lower than 30 yo.
  • Systemic condition
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00407121


Locations
Mexico
Asociacion para Evitar la Ceguera en Mexico
Mexico, Distrito Federal, Mexico, 04030
Sponsors and Collaborators
Asociación para Evitar la Ceguera en México
Investigators
Principal Investigator: Veronica Kon-Jara, MD Asociación para Evitar la Ceguera en México
Study Chair: LuzElena Concha-Del Rio, MD Asociación para Evitar la Ceguera en México
  More Information

ClinicalTrials.gov Identifier: NCT00407121     History of Changes
Other Study ID Numbers: APEC-0025
First Submitted: December 1, 2006
First Posted: December 4, 2006
Last Update Posted: December 4, 2006
Last Verified: December 2006

Keywords provided by Asociación para Evitar la Ceguera en México:
Neovascular Membrane
Uveitis
Bevacizumab

Additional relevant MeSH terms:
Uveomeningoencephalitic Syndrome
Choroiditis
Choroid Diseases
Uveal Diseases
Eye Diseases
Uveitis, Posterior
Panuveitis
Uveitis
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Autoimmune Diseases
Immune System Diseases
Bevacizumab
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents